期刊文献+

环孢素A-Eudragit S100纳米粒的制备及其体内外评价 被引量:10

Study on Preparation of CyA-Eudragit S100-Nanoparticles and Its Characteristics in Vivo and in Vitro
暂未订购
导出
摘要 目的制备环孢素A-Eudragit S100纳米粒,并考察相关特性;以新山地明(Neoral()为参比制剂,考察大鼠体内药动学及相对生物利用度。方法以溶剂-非溶剂法联合冷冻干燥技术制备环孢素A-Eudragit S100纳米粒(CyA-NP)胶体溶液及其冻干粉末(Fd-CyA-NP);动态透析法研究其体外释药动力学;以新山地明(Neoral)为对照,大鼠分别灌胃3种制剂后,HPLC测定全血中的CyA浓度,3P97程序计算药动学参数。结果CyA-NP和Fd-CyA-NP的平均粒径分别为(44.8±3.2)和(55.7±3.6)nm;包封率大于90%;电镜下呈均匀规则的圆球形;且2种制剂在pH>6.0的释放介质中释药速率明显增大,具有显著pH敏感性;3种制剂均符合二室模型,CyA-NP和Fd-CyA-NP的相对生物利用度分别为Neoral(的162.1%和130.1%。结论以pH敏感性材料Eudragit S100为载体有望开发成一种高效、低毒的环孢素A纳米制剂。 OBJECTIVE To study the preparation and pharmaceutical characteristics of cyclosporine A-Eudragit S100- nanoparticles (CyA-NP) in vitro and in vivo by using Neoral as reference preparation. METHODS CyA-NP were prepared with quasi-emulsion solvent diffusion technique and freeze-drying technique. Dynamic dialyse method was used to study the release dynamics of the three kinds of nanoparticles in vitro. The bioavailability of CyA-NP and freeze-drying nanoparticles was determined by HPLC and its pharmacokinetics parameters were calculated by 3P97 program. RESULTS The particle sizes of CyA-NP and Fd-CyA-NP were (44. 8±3.2) and (55.7 ± 3.6) nm. The encapsulation efficiency of CyA was 90%. The drug-loaded nanoparicles were spherical observed by the transmission electric microscope. The release study in vitro showed evidently pH-sensitive when the medium pH were over 6.0. The relative bioavailability of CyA-NP and Fd-CyA-NP were 162. 1% and 130.1% compared with Neoral. CONCLUSION pH-sensitive Eudragit S100 was a potential carrier material in developing a high performance CyA nanometer system with low toxicity.
机构地区 苏州大学药学院
出处 《中国药学杂志》 CAS CSCD 北大核心 2008年第23期1798-1803,共6页 Chinese Pharmaceutical Journal
基金 江苏省科技厅社会发展项目资助(BS200522) 江苏省高校高新技术产业发展项目资助(JHB05-46) 江苏省卫生厅招标课题(编号:H200630) 国家大学生创新实践课题(57315420)
关键词 环孢素A pH敏感性纳米粒 冻干粉末 相对生物利用度 cyclosporine A pH-sensitive nanoparticle freeze-drying powder relative bioavailability
  • 相关文献

参考文献10

  • 1YEE G C, MC GURE T R. Pharmacokinetic drug interactions with cyclosporine ( part I ) [ J ]. Clin Pharmacokinet, 1990,19 (4) : 319 - 332.
  • 2LUKE D R, KASISKE B L, MATZKE G R,et al. Effect of cyclosporin on the isolated perfused rat kidney [ J ]. Transplantation, 1987,43 (6) : 795-799.
  • 3DESAI M P, LABHASETWAR V, AMIDON G L, et al. Gastrointestinal of biodegradable microparticles [ J ]. Pharm Res, 1996,13(12) :1838-1845.
  • 4戴俊东 ,王学清 ,张涛 ,孟萌 ,张烜 ,吕万良 ,张强 .环孢素A pH敏感性纳米粒的制备与大鼠口服药代动力学[J].药学学报,2004,39(12):1023-1027. 被引量:12
  • 5黎洪珊,叶国庆,赵京玲,魏树礼.改良的HPLC法测定大鼠和家兔全血中的环孢菌素A[J].华西药学杂志,1999,14(2):89-92. 被引量:8
  • 6MALMARY M F, HOUTI I. Chronopharmacokineties of eyclosporine A following a single iv, dose in the wistar rat [ J ]. Eur J Pharm Sci, 1995,3( 1 ) :49-56.
  • 7TJAI J F, WEBBER I R, BACK D J. Cyclosporin metabolism by the gastrointestinal mucosa[ J]. Br J Clin Pharmacol, 1991, 31 ( 3 ) : 344-346.
  • 8DREWE J, BEGLINGER C, KISSEL T. The absorption site of cyclosporin in the human gastrointestinal tract [ J ]. Br J Clin Pharmcol, 1992, 33( 1 ) :39-43.
  • 9CHACON M, MOLPECERES J, BERGES L. Stability and free-zedrying of cyclosporine loaded poly ( D, L-lactide-glycolide ) carriers[J]. Eur J Pharm Sci, 1999( 8 ) :99-107.
  • 10LEE E J, LEE S W, CHOI H G, et al. Bioavailability of cyelos-porine A dispersed in sodium lauryl sulfate dextrin based solid microspheres [ J ]. Int J Pharm, 2001,218 ( 1-2 ) : 125 -131.

二级参考文献12

  • 1李克,王平,袁倚盛,柳晓泉.单步萃取-反相高效液相色谱法测定人全血中环孢菌素A及其药动学参数[J].中国药学杂志,1997,32(3):157-161. 被引量:26
  • 2Lindholm A, Henricsson S, Lind M, et al. Intraindividual variability in the relative availability of cyclosporin after oral dosing [ J ] . Eur J Clin Pharmacol,1988,34 (5) :461 - 464.
  • 3Tjai JF, Webber IR, Back DJ. Cyclosporin metabolism by the gastrointestinal mucosa [ J ]. Br J Clin Pharmacol,1991,31(3) :344 -346.
  • 4Noble S, Markham A. Cyclosporin: a review of pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation(Neoral) [J]. Drugs, 1995,50(5):924-941.
  • 5Luke DR, Kasiske BL, Matzke GR, et al. Effect of cyclosporin on the isolated perfused rat kidney [ J ].Transplantation, 1987,43:795-799.
  • 6Cavanak T, Sucker H. Cyclosporin. Formulation of dosage forms [J]. Prog Allergy, 1986,38:65 -72.
  • 7Kawashima Y, Niwa T, Handa T, et al. Preparation of controlled-release microspheres of ibuprofen with acrylic polymers by a novel quasi-emulsion solvent diffusion method [J]. J Pharm Sci, 1989,78( 1 ) :68 -72.
  • 8Malmary MF, Houti I, Labat C, et al.Chronopharmacokinetics of cyclosporine A following a single iv dose in the Wistar rat [ J ]. Eur J Pharm Sci,1995,3( 1 ) :49 -56.
  • 9McClean S, Prosser E, Meehan E, et al. Binding and uptake of biodegradable polydl- lactide micro- and nanoparticles in intestinal epithelia [ J ]. Eur J Pharm Sci, 1998,6(2) :153 - 163.
  • 10Desai MP, Labhasetwar V, Amidon GL, et al.Gastrointestinal uptake of biodegradable microparticles:effect of particle size [ J]. Pharm Res, 1996,13(12):1838 - 1845.

共引文献18

同被引文献2094

引证文献10

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部